For the quarter ending 2025-09-30, ETON made $22,459K in revenue. -$1,927K in net income. Net profit margin of -8.58%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total net revenues | 22,459 | 18,928 | 17,282 | 10,324 |
| License | 0 | 0 | - | - |
| Product Sales And Royalties | 14,604 | 7,004 | - | - |
| Total cost of sales | 14,604 | 7,004 | 7,421 | 4,022 |
| Gross profit | 7,855 | 11,924 | 9,861 | 6,302 |
| Research and development | 1,112 | 3,712 | 1,161 | 505 |
| General and administrative | 8,106 | 9,687 | 9,170 | 5,288 |
| Total operating expenses | 9,218 | 13,399 | 10,331 | 5,793 |
| Income (loss) from operations | -1,363 | -1,475 | -470 | 509 |
| Interest and other expense, net | -592 | -1,044 | -1,028 | -8 |
| Us-gaap_nonoperatingincomeexpense | - | - | - | -8 |
| Income (loss) before income tax expense | -1,955 | -2,519 | -1,498 | 501 |
| Income tax expense (benefit) | -28 | 66 | 74 | -126 |
| Net income (loss) | -1,927 | -2,585 | -1,572 | 627 |
| Net income (loss) per share, basic (in dollars per share) | -0.07 | -0.1 | -0.06 | 0.02 |
| Net income (loss) per share, diluted (in dollars per share) | -0.07 | - | - | 0.02 |
| Weighted average number of common shares outstanding, basic (in shares) | 26,893,000 | 26,893,000 | 26,886,000 | 25,900 |
| Weighted average number of common shares outstanding, diluted (in shares) | 26,893,000 | - | - | 26,550 |
Eton Pharmaceuticals, Inc. (ETON)
Eton Pharmaceuticals, Inc. (ETON)